Table 1.
Clinical characteristics of the enrolled participants in this study (n = 654).
| Training set (442) | Test set (212) | |||
|---|---|---|---|---|
| HBVLD (n = 230) | Early HCC (n = 212) | HBVLD (n = 111) | Early HCC (n = 101) | |
| Age (years, mean ± SD) | 45.37 ± 11.9 | 46.22 ± 11.7 | 45.38 ± 12.08 | 52.24 ± 10.36 |
| Sex (M/F) | 170/60 | 174/38 | 80/31 | 90/11 |
| ALT (U/L) | ||||
| <40 | 108 (47.0%) | 128 (60.4%) | 51 (45.9%) | 60 (59.4%) |
| ≥40 | 121 (52.6%) | 83 (39.2%) | 60 (54.1%) | 41 (40.6%) |
| AST (U/L) | ||||
| <40 | 125 (54.3%) | 140 (66.0%) | 59 (53.2%) | 55 (54.5%) |
| ≥40 | 104 (45.2%) | 71 (30.9%) | 52 (46.8%) | 46 (44.5%) |
| Total bilirubin (μmol/L) | ||||
| <21 | 144 (62.6%) | 147 (69.3%) | 79 (71.1%) | 63 (62.4%) |
| ≥21 | 85 (37.0%) | 64 (30.2%) | 32 (18.9%) | 38 (37.6%) |
| Direct bilirubin (μmol/L) | ||||
| <7 | 169 (73.5%) | 175 (82.5%) | 88 (79.3%) | 72 (71.3%) |
| ≥7 | 60 (26.1%) | 36 (17.0%) | 23 (20.7%) | 29 (28.7%) |
| Total protein (g/L) | ||||
| <65 | 168 (73.4%) | 135 (59.0%) | 85 (76.6%) | 65 (64.4%) |
| ≥65 | 61 (26.5%) | 76 (35.8%) | 26 (23.4%) | 36 (35.6%) |
| Albumin (g/L) | ||||
| <40 | 136 (59.1%) | 105 (49.5%) | 72 (64.9%) | 45 (44.6%) |
| ≥40 | 93 (40.4%) | 106 (50.0%) | 39 (35.1%) | 56 (55.4%) |
| γ-GT (U/L) | ||||
| <45 | 121 (52.6%) | 95 (44.8%) | 52 (46.8%) | 40 (39.6%) |
| ≥45 | 96 (41.7%) | 95 (44.8%) | 52 (46.8%) | 61 (60.4%) |
| Alkaline phosphatase (U/L) | ||||
| ≤100 | 172 (74.8%) | 142 (67.0%) | 83 (74.8%) | 48 (47.5%) |
| >100 | 46 (20.0%) | 48 (22.6%) | 22 (19.8%) | 37 (36.6%) |
| WBC count × 109/L | ||||
| <3.5 | 174 (75.7%) | 157 (74.1%) | 79 (71.2%) | 74 (73.3%) |
| 3.5–9.5 | 46 (20.0%) | 42 (19.8%) | 24 (21.6%) | 14 (13.9%) |
| >9.5 | 10 (4.3%) | 12 (5.7%) | 8 (7.2%) | 13 (12.9%) |
| Hemoglobin (g/L) | ||||
| <130 | 143 (62.2%) | 138 (65.1%) | 77 (69.4%) | 60 (59.4%) |
| ≥130 | 87 (37.8%) | 73 (34.4%) | 34 (30.6%) | 41 (40.6%) |
| Platelet count × 109/L | ||||
| <125 | 129 (56.1%) | 108 (50.9%) | 70 (63.1%) | 58 (57.4%) |
| ≥125 | 101 (43.9%) | 104 (49.1%) | 41 (36.9%) | 43 (42.6%) |
| Lymphocyte count × 109/L | ||||
| <1.1 | 172 (74.8%) | 149 (70.3%) | 85 (76.6%) | 58 (57.4%) |
| ≥1.1 | 58 (25.2%) | 62 (29.2%) | 26 (23.4%) | 43 (42.6%) |
| Monocyte count × 109/L | ||||
| <0.6 | 214 (93.1%) | 182 (85.8%) | 107 (96.4%) | 81 (80.2%) |
| ≥0.6 | 16 (6.9%) | 29 (13.7%) | 4 (3.6%) | 20 (19.8%) |
| Neutrophil count × 109/L | ||||
| <1.8 | 166 (72.2%) | 167 (78.8%) | 80 (72.1%) | 71 (70.3%) |
| 1.8–6.3 | 53 (23.0%) | 17 (8.0%) | 26 (23.4%) | 12 (11.9%) |
| >6.3 | 11 (4.8%) | 17 (8.0%) | 5 (4.5%) | 18 (17.8%) |
| Alpha-fetoprotein (ng/ml) | ||||
| <20 | 178 (77.4%) | 110 (51.9%) | 86 (77.5%) | 41 (40.6%) |
| ≥20 | 50 (21.7%) | 96 (45.3%) | 25 (22.5%) | 58 (57.4%) |
HBVLD, HBV-related liver disease; CHB, chronic hepatitis B; LC, HBV-related liver cirrhosis; HCC, hepatocellular carcinoma; BCLC, Barcelona clinic liver cancer staging system; γ-GT, γ-glutamyltranspeptidase; WBC, white blood cell. ALT, alanine aminotransferase; AST, aspartate aminotransferase.